Omeprazole controlled release - Flamel Technologies

Drug Profile

Omeprazole controlled release - Flamel Technologies

Alternative Names: Omeprazole XL

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Flamel Technologies
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes - Gastro-oesophageal reflux

Highest Development Phases

  • No development reported Gastro-oesophageal reflux

Most Recent Events

  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux in Europe (PO, Controlled release)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top